Biotechnology Market News

New Study Links Schizophrenia, Autism - TopNews

New Study Links Schizophrenia, Autism TopNews, India - 1 hour ago The new study has found that rare and previously undetectable genetic variations may significantly increase the risk that a person will develop ...

MSA hopes to address misconceptions about Islam - The Daily Evergreen

MSA hopes to address misconceptions about Islam The Daily Evergreen, WA - 1 hour ago ... about Islam and give more accurate information other than the mediaa s portrayal,a said Naima Abshir, a junior genetics major and MSA vice president. ...

Keel Laying Takes Place for Tenth Vessel Built at Aker ... - PR-Inside.com (Pressemitteilung)

Keel Laying Takes Place for Tenth Vessel Built at Aker ... PR-Inside.com (Pressemitteilung), Austria - 6 hours ago ... global companies, leaders in global growth markets including energy technologies, energy resources, maritime technologies, seafood and marine biotechnology.

Giving Patients a Voice in Treatment - UC Los Angeles

Giving Patients a Voice in Treatment UC Los Angeles, CA - 2 hours ago ... provost of intellectual property and industrial relations, was quoted Friday in a Ventura County Star article about Californiaa s biotechnology industry. ...

Slow catch-up time just understanding what genetic screening can do - Longview Daily News

Slow catch-up time just understanding what genetic screening can do Longview Daily News, WA - 18 minutes ago Fueled by the galloping pace of genomic research, new tests are being stocked daily. Thinking about shoring up your personal health future? ...

Alpha Innotech Reports 20% Fourth Quarter Revenue Growth - StreetInsider.com (subscription)

Alpha Innotech Reports 20% Fourth Quarter Revenue Growth StreetInsider.com (subscription), MI - 1 hour ago Our goal is to combine instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, ...

Getting personal - Deccan Herald

Getting personal Deccan Herald, India - 1 hour ago More than 20 companies today offer "personalised genomics" tests that promise to help clients discern from their DNA what diseases they are likely to get, ...

BGI Partners with PentaBase to Develop PCR-Based Dx Kits - GenomeWeb News (subscription)

BGI Partners with PentaBase to Develop PCR-Based Dx Kits GenomeWeb News (subscription), NY - 2 hours ago By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) a The Beijing Genome Institute and the Danish diagnostic developer PentaBase have agreed to ...

Drug Data Take Sword to Schering-Plough - Smartmoney.com

Drug Data Take Sword to Schering-Plough Smartmoney.com - 55 minutes ago Michael King, an analyst with biotechnology research firm Rodman & Rensaw, wrote in a Monday note that the study seemed too specific and raised more ...

NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update

HUBBARD, Ohio, March 31 /PRNewswire-FirstCall/ -- NanoLogix, Inc. a nano-biotechnology company is pleased to provide the following updates on company events:

NanoLogix personnel are manning a booth and presenting at the National Hydrogen Association Expo in Sacramento this week, with the company being represented by William Hartman and Chris Novak. Mr. Hartman will be presenting in the Exhibition Hall today, March 31, from 2:00-2:30 pm, on "Biohydrogen and Electricity Production from Waste Water".

Company CEO Bret Barnhizer was Marlene Bourne's guest on The Bourne Report March 16, on the topic of Hydrogen Power. The interview provides updates on hydrogen bioreactor operations. Access: http://www.bournereport.com/radio.php

Work on BNC and BNP development for fast microorganism detection is proceeding at a rapid pace, with a new patent application filed in March and positive developments with both the Departments of Defense and Homeland Security in late February.

Director and Management changes: Dr. Robert Ollar and John Chatterton have joined the Board of Directors. Dr. Ollar is cofounder of NanoLogix (as Infectech), the primary author of the majority of the company's granted patents, and returns to the company after a six year hiatus. Mr. Chatterton is former co-host of the History Channel series, Deep Sea Detectives, and is one of the world's most accomplished and well known underwater explorers. David Barnhizer has joined the company as General Counsel, bringing to the company nearly forty years of legal expertise. Detailed director and management team information can be accessed at: http://www.nanologixinc.com/index-2.html

General Counsel David Barnhizer stated: "NNLX is poised to make a significant move forward under its new board of directors and management team headed by CEO and Board Chairman Bret Barnhizer and complemented by a reformed and greatly strengthened board of directors. A skilled and knowledgeable team of professionals whose members are fully dedicated to the advancement of NanoLogix has been put into place. As NNLX General Counsel I am extremely pleased to be associated with a group of professionals committed to the building of an exceptional company whose patented technologies are on the cutting edge of hydrogen energy extraction from industrial and commercial wastes, as well as diagnostic tools that are drawing the attention of governmental and commercial institutions."

The company has accepted the resignations of directors Hartman, Allan, and Cavallo from all positions held. Mr. Hartman will continue to provide business consulting services to NanoLogix.

About NanoLogix, Inc.

NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and multiple Patents Pending for bioreactor- based Hydrogen Production, revolutionary rapid medical testing technologies, and bioremediation. Information on NanoLogix is available at http://www.nanologixinc.com/.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact: Investor Relations Bret Barnhizer, CEO Telephone: 330-534-0800 E-mail: Bret@nanologixinc.com

NanoLogix, Inc.

CONTACT: Investor Relations, Bret Barnhizer, CEO, NanoLogix, Inc.,
1-330-534-0800, Bret@nanologixinc.com

Web site: http://www.nanologixinc.com/
http://www.bournereport.com/radio.php
http://www.nanologixinc.com/index-2.html

febit Forms Scientific Advisory Board - FOXBusiness

febit Forms Scientific Advisory Board FOXBusiness - 2 hours ago Jeffrey Trent, Ph.D., the president and scientific director of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. ...

Pro-Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ... - Lifescience-online

Pro-Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ... Lifescience-online, Switzerland - 39 minutes ago Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of first-in-class, carbohydrate-based targeted therapeutic compounds, today reported its fourth quarter ...

Transave, Inc. Raises 5 Million Through Series D Convertible Preferred Stock Financing

MONMOUTH JUNCTION, N.J., March 31 /PRNewswire/ -- Transave, Inc., a biopharmaceutical company focused on developing innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases today announced that it has raised an aggregate of 5 million pursuant to its recently completed preferred stock offering. Joining the Company's Board are Richard Kollender from Quaker BioVentures and Steve Kraus from Bessemer Venture Partners, the lead investors in the Series D financing. Also participating in the financing were TVM Capital, Prospect Venture Partners, Fidelity Biosciences, Forbion Capital Partners and Easton Capital, all having previously taken a leading investment role in Transave.

"Proceeds from the financing will enable Transave to deliver Phase II proof of concept data for our lead clinical compound, ARIKACE(TM) (liposomal amikacin for inhalation). We are on track to have Arikace Phase II clinical data in cystic fibrosis patients that have Pseudomonas lung infections this year. In addition, Phase II bronchiectasis data will be available in the first half of 2009," said Tim Whitten, President and Chief Executive Officer of Transave.

Tim Whitten further commented, "We extend a hearty welcome to our newest Board Members, Rich Kollender and Steve Kraus who will add further depth to our Board. It is gratifying to receive significant financial support, not only from our highly-regarded new investors, but also from our existing investors. The new funding serves to validate the great strides Transave is making in our clinical programs based on our once-daily, next-generation liposomal pulmonary delivery technology. And perhaps more importantly, this financing will allow us to continue our mission to help patients that have serious chronic pulmonary infections."

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States in the absence of an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the convertible preferred stock.

About ARIKACE (liposomal amikacin for inhalation)

ARIKACE is a form of the antibiotic amikacin that is enclosed in nanocapsules of lipid called liposomes. This proprietary next-generation liposomal technology prolongs release of amikacin in the lung while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 mm) neutrally charged liposomes that enable biofilm penetration and are highly efficient with very low lipid to drug ratio (0.6). ARIKACE can be effectively delivered through nebulization where the small aerosol droplet size (~3.0 mm) facilitates lung distribution. Two Phase II studies are currently being conducted in patients that have CF and Pseudomonas lung infections in Europe and the United States. An abstract on the top line European Phase II data in CF has been accepted for presentation at the 31st European Cystic Fibrosis Conference in Prague in June. ARIKACE has been granted orphan drug status in the United States by the FDA and orphan drug designation in Europe by the European Medicines Agency (EMEA) for the treatment of Pseudomonas infections in patients with CF.

About Transave Inc.

Transave Inc is a biopharmaceutical company focused on the development of innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. The company's major focus is developing antibiotic therapy delivered via next-generation liposomal technology in areas of high unmet need in respiratory disease. Transave is dedicated to leveraging its advanced liposomal development and commercialization expertise, along with its intellectual property, to bring life extending and enhancing medicines to patients.

For more information about Transave's technology and development programs, visit http://www.transaveinc.com/.

Transave, Inc.

CONTACT: Jennifer Corrigan, 1-732-382-8898, jenn.corrigan@comcast.net

Web site: http://www.transaveinc.com/

febit Forms Scientific Advisory Board - FOXBusiness

febit Forms Scientific Advisory Board FOXBusiness - 14 minutes ago Dr. Chee added, "It is our goal to help febit meet scientists' needs and open up new possibilities in genomic research. febit's Geniom technology is a ...

Stellar Pharmaceuticals Announces Profitability for 2007 Fourth ... - CNNMoney.com

Stellar Pharmaceuticals Announces Profitability for 2007 Fourth ... CNNMoney.com - 4 hours ago Stellar also has an in-licensing agreement for NMP22 BladderChek , a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. ...

Biography of Courage and Medical Innovation Top Choice of Readers, Editors and Publishers

TORONTO, Canada, March 31 /PRNewswire/ -- The book Lifeliner by Shireen Jeejeebhoy has just scooped awards for Editors Choice and Publishers Choice as well as winning first place in the Reader Views Reviewers Choice Award for biographies.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080331/298826 )

The book, available from iUniverse, Barnesandnoble.com, Amazon and Chapters, tells the story of the first 'lifeliner' Judy Taylor. She survived over 20 years living with a permanent catheter, in which she received total parenteral nutrition (TPN) thanks to a radical young doctor Dr Khursheed Jeejeebhoy.

Due to the success of his groundbreaking research on artificial feeding for humans, Dr Jeejeebhoy has been called "the father of long-term parenteral nutrition in man." His daughter Shireen met Judy while a young girl, and was inspired to share Judy Taylor's story in her book Lifeliner to offer hope for other TPN patients.

Shireen says: "Research medicine often has its critics, but the combination of hope, desire to live, and a doctor willing to experiment with innovative medical procedures, opens doors for many patients whose lives are on the line."

After Judy Taylor's intestinal blood clots annihilated her digestive system, her only choice was starving to death until Dr. Jeejeebhoy agreed to take her on as a human test subject.

Twenty years followed during which Judy enjoyed life, raising her children and loving her husband. During those twenty years she never ate a meal, having to rely on intravenous feeding. Yet she was able to participate in a fulfilling life thanks to TPN.

According to the Oley Foundation in the US, cited by the International Foundation for Functional Gastrointestinal Disorders, the number of people on tube feedings/enteral nutrition today is currently estimated to be 176,000, and the number on parenteral nutrition is estimated at 46,000 in the US.

Judy Taylor, along with her determined doctor, helped bring TPN out of the realm of science fiction and into reality, allowing more patients to live longer, fulfilled lives.

Notes to Editors: About the Author Shireen Jeejeebhoy was born in London and lives in Toronto, Canada.

She holds a BSc in Psychology from the University of Toronto. She is available for phone interviews. To arrange please contact 1-416-838-8297.

Lifeliner: The Judy Taylor Story by Shireen Jeejeebhoy iUniverse October 2007 / 186 pages ISBN: 978-0-595-44544-8 Trade Paper US6.95 Contact details: Shireen Jeejeebhoy, shireen@jeejeebhoy.ca; http://jeejeebhoy.ca/.

Photo: http://www.newscom.com/cgi-bin/prnh/20080331/298826 Shireen Jeejeebhoy

CONTACT: Contact details: Shireen Jeejeebhoy, shireen@jeejeebhoy.ca;
She is available for phone interviews. To arrange please contact
1-416-838-8297.

Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers Kingfisher's Revolutionary Device Designed to Improve Quality of Life for Patients Suffering From Chronic Pain

ALBUQUERQUE, New Mexico, March 31 /PRNewswire/ -- Kingfisher Americas, a healthcare company focused on improving patient quality of life, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market KFH Energy in the United States. The patented, high-tech medical device is intended to improve upon quality of life for sufferers of chronic pain associated with post-polio syndrome, fibromyalgia, multiple sclerosis, and chronic fatigue syndrome.

"We are thrilled to introduce KFH Energy to physicians, specialists, and patients throughout the United States," said Dr. Henk Snyman, CEO and co-founder of Kingfisher Healthcare, the parent company of Kingfisher Americas. "Our clinical research on post-polio patients yielded dramatic improvements, and we are eager to address the strong population of chronic pain patients in the U.S. With the proven success of KFH Energy, we anticipate that this technology will be the first in a suite of natural energy devices for a variety of treatments."

KFH Energy utilizes a unique form of micro current electrotherapy called Bio-Electric Stimulation Therapy (BEST), which is designed to enhance the body's physiological processes. Intended for home use, KFH Energy encapsulates this novel technology in a hand-held device. Its sleek and modern design elements, including the patented touch-screen panel, make the device both convenient and easy to use. KFH Energy received CE mark in Europe in September 2007.

"There is a growing demand among individuals with chronic pain for alternative treatments to improve their condition," said Herb Whitaker, CEO of Kingfisher Americas. "We are excited to have this device available in the States and are committed to improving the lives of those who have been sidelined as a result of symptoms."

For more information about KFH Energy and its availability in the U.S., please visit http://www.kfamericas.com/ or http://www.kfhealth.com/.

About Kingfisher Americas

Kingfisher Americas, a subsidiary of the Belgium-based Kingfisher Healthcare, is the first company to use safe, non-invasive energy to treat patients suffering from chronic conditions. It utilizes a technology platform called BEST (Bio-Electric Stimulation Therapy) from which unique products are developed by Kingfisher Healthcare. Headquartered in Albuquerque, New Mexico, Kingfisher Americas focuses on establishing relationships with patients, patient support groups, and medical experts to improve the quality of life of fibromyalgia, post polio, and chronic fatigue syndrome patients. For more information, please visit http://www.kfamericas.com/.

Kingfisher Americas

CONTACT: Media Contacts: Roy Whitaker, Kingfisher Americas,
1-877-252-4374 x 708, r.whitaker@kfamericas.com; Jackie Hanley, Racepoint
Group, 1-781-487-4625, jhanley@racepointgroup.com

A step closer to a global eugenic biological cleansing possiblitity (Weazl's Revenge)

Synosia Starts Phase II Efficacy Trial For Rufinamide Epilepsy Drug to be Tested as Treatment for Anxiety Synosia Therapeutics today announced the start of a multi-site, Phase II clinical trial to evaluate the efficacy of rufinamide (SYN-111), a sodium c

BASEL, Switzerland, March 31 /PRNewswire/ -- The trial is an eight-week, double-blind, placebo-controlled, exploratory study being conducted in 20 sites in the United States. It will assess the efficacy and tolerability of rufinamide in up to 230 patients with general anxiety disorder, as measured by multiple psychometric assessment tools. Patients randomized to rufinamide will receive 250mg twice a day for one week followed by 500mg twice a day for seven weeks. The trial design was guided by the encouraging results of a proof-of-concept study announced in January 2008.

Rufinamide was discovered and developed by Novartis. Rights to SYN-111 were obtained by Synosia from Novartis in 2007 in an exclusive worldwide licensing agreement, outside of Japan, to develop and commercialize rufinamide for the treatment of anxiety and other mood disorders. Rufinamide is also marketed by Eisai in Europe as a drug to treat a form of epilepsy under the tradename Inovelon(R).

"Given the extensive safety experience available from previous studies, we believe this structurally novel compound has the potential to relieve anxiety without the adverse side effects of current treatments," said Stephen Bandak, Synosia's chief medical officer. "There is a real need for new treatment options without the limited compliance associated with selective serotonin reuptake inhibitors (SSRIs) or the risk of dependence of benzodiazepine-based treatments."

It is estimated that over 62 million people in the United States and the five major European pharmaceutical markets suffer from a form of anxiety. Of those, over nine million suffer from general anxiety disorder.(1),(2)

About Rufinamide

The drug was originally discovered and developed by Novartis, which in 2004 granted certain licensing rights to Eisai, excluding anxiety and mood disorders. In January 2007, Eisai received marketing authorisation in the European Union for Inovelon(R) (rufinamide) as adjunctive anti-epileptic therapy in Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy that develops in early childhood. The extensive clinical development program for rufinamide in epilepsy has generated over 2500 patient years of exposure to the drug.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company has six clinical-stage compounds in its pipeline, acquired through key partnerships with Novartis, Roche and Syngenta. Synosia's pipeline includes two marketed drugs that will be tested in new indications, extending their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's Disease. Synosia's headquarters is in Basel, Switzerland. For more information visit http://www.synosia.com/

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Synosia Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

References

(1) Demyttenaere et al. Prevalence, Severity, and unmet needs for treatment of mental disorders in the WHO World Mental Surveys. JAMA (2004) vol. 291 (21) pp. 2581-90.

(2) Kessler et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) vol. 62 (6) pp. 593-602.

Synosia Therapeutics

CONTACT: Contact: Synosia Therapeutics, Julie Walters at Tudor Reilly,
Tel: 44(0)1494-753-990, Mobile 44(0)775-3626967,
julie.walters@tudor-reilly.com; In the US, Michele Parisi at Tudor Reilly,
Tel: 1-925-864-5028, michele.parisi@tudor-reilly.com; In Switzerland: Martin
Meier-Pfister or Jan Gregor at The IR Firm, Tel: 41-43-244-81-54, Mobile:
41-79-652-36-20, synosia@irfirm.biz

Vaccine for Ebola virus (Physorg)

One of the world s deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use.

Best Biotechnology Web Site Trends Detailed in New Report from Web ... - Emediawire (press release)

Best Biotechnology Web Site Trends Detailed in New Report from Web ... Emediawire (press release), WA - 1 hour ago Despite scoring the third highest score in copywriting across all industries judged, the biotechnology industry scored below the 5-year criteria benchmark ...

Not so odd jobs: Farmers stay in ag arena with extra employment - Bloomington Pantagraph

Not so odd jobs: Farmers stay in ag arena with extra employment Bloomington Pantagraph,  USA - 2 hours ago Through Royal Seed, he stores and sells Midwest Seed Genetics. Lawnmowers, tractors and other implements are a newer addition to the Fairbury business this ...

Future mobile phones will have blazing speed, biochips to diagnose ... - EETimes.com

Future mobile phones will have blazing speed, biochips to diagnose ... EETimes.com - Mar 27, 2008 If Japan's NTT DoCoMo has its way, future mobile phones will feature data speeds of 250 Mbps and biochips that could analyze a drop of blood or sweat for ...

Tekmira Pharmaceuticals Releases 2007 Audited Operating Results - Market Wire (press release)

Tekmira Pharmaceuticals Releases 2007 Audited Operating Results Market Wire (press release) - 46 minutes ago ... under which Tekmira was spun out from Inex Pharmaceuticals Corporation with Inex's entire biotechnology business, assets and intellectual property. ...

Collaboration key to success for NZ sheep genome - Scoop.co.nz (press release)

Collaboration key to success for NZ sheep genome Scoop.co.nz (press release), New Zealand - 25 minutes ago Meat & Wool New Zealand, AgResearch and Ovita today announced that an important phase of an international project to map the sheep genome has taken a big ...

Bowel cancer genetic risk 'depends on race' - InTheNews.co.uk

Bowel cancer genetic risk 'depends on race' InTheNews.co.uk, UK - 2 hours ago Researchers at the University of Edinburgh found that a genetic marker is associated with an increased risk of colon cancer in Europeans, but not in the ...

Assault in the 4th Ward - Hoboken411.com

Assault in the 4th Ward Hoboken411.com, NJ - 1 hour ago Is it parenting, genetics, lifestyle choice spurred by current trends, a combination of all of these. Who knows. The new population in the luxury condos are ...

Iowa Business Briefs: Genome talk to cover present, future - DesMoinesRegister.com

Iowa Business Briefs: Genome talk to cover present, future DesMoinesRegister.com, IA - 12 hours ago The lecture will discuss possible uses of the corn genome map, other genomes and the future of genome research. Schnable participates in the Maize Genome ...

Future Mobile Phones Will Have Blazing Speed, Biochips To Diagnose ... - InformationWeek

Future Mobile Phones Will Have Blazing Speed, Biochips To Diagnose ... InformationWeek, NY - Mar 27, 2008 In the biochip work, DoCoMo said its experiments with researchers at the University of Toyko were able to successfully demonstrate what it calls "the ...

Pet DNA Helps Investigators Take a Bite Out of Crime - FOXNews

Pet DNA Helps Investigators Take a Bite Out of Crime FOXNews - 1 hour ago By Casey Stegall AP Beth Wictum, left, acting director of the Veterinary Genetics Laboratory at the University of California, Davis, points out areas to ...